Antiviral drugs and plasma therapy used for Covid-19 treatment: a nationwide Turkish algorithm


NADAROĞLU H.

DRUG METABOLISM REVIEWS, cilt.52, sa.4, ss.531-539, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 52 Sayı: 4
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1080/03602532.2020.1803907
  • Dergi Adı: DRUG METABOLISM REVIEWS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, BIOSIS, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.531-539
  • Anahtar Kelimeler: COVID-19, Antiviral drugs, plasma treatment, Turkey algorithm, EBOLA-VIRUS, CORONAVIRUS, NITAZOXANIDE, FAVIPIRAVIR, SARS, CHLOROQUINE, PATIENT
  • Atatürk Üniversitesi Adresli: Evet

Özet

The Coronavirus outbreak described as COVID-19 is an insidious and enormous biohazard which began to be noticed in November 2019. When the virus was determined to cause serious upper respiratory tract infections resulting in death, pandemics were declared in the world. As of today, the number of cases exceeded 221 thousand people in Turkey, the number of patients who died had reached 5526. In more than 200 countries around the world, 15.1 million people fight the disease, while the number of people recovered is over 9.134 million, and the number of deaths has exceeded 620 thousand. The top 5 countries in the world are USA, Brazil, Russia, India and Spain. The countries with the highest number of cases after America (approximately 4 million 28 thousand) are Brazil (approximately 2 million 166 thousand), India (about 1 million 195 thousand), Russia (approximately 789 thousand), South Africa (approximately 382 thousand). In addition, the number of deaths and cases caused by Covid 19 continues to increase day by day. In this review, it was aimed to discuss that Covidien-19 against antiviral drugs used in the struggle across the globe and plasma treatment options about the current state of knowledge and Turkey algorithm by comparing the therapeutic treatment options.